Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

  • End date
    Oct 9, 2023
  • participants needed
  • sponsor
    ValenzaBio, Inc.
Updated on 9 September 2021
monoclonal antibodies
treatment regimen
follicle stimulating hormone
kidney biopsy


This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN

Condition Membranous glomerulonephritis, Glomerulonephritis, Autoimmune disease, membranous nephropathy
Treatment VB119
Clinical Study IdentifierNCT04652570
SponsorValenzaBio, Inc.
Last Modified on9 September 2021


Yes No Not Sure

Inclusion Criteria

Is 18 years of age at the time of informed consent
Has a kidney biopsy-proven diagnosis of primary MN within the past 10 years; Note: It is preferable that subjects enrolled have kidney biopsy tissue samples that are positive for anti-PLA2R antibody staining. Subjects with kidney biopsy-proven diagnosis of primary MN >10 years and 20 years that meet all other eligibility criteria may be enrolled after discussion with the Medical Monitor
Has proteinuria with a UPCR 3.5 g/g, based on 2 consecutive 24-hour urine sample collections obtained within 14 days of each other during the Screening Period. Both samples must qualify
Has systolic blood pressure (BP) <160 mmHg or diastolic BP <100 mmHg after 5 minutes of rest at Screening
Is willing and able to provide written informed consent prior to Screening
Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone in the postmenopausal range at Screening, based on the central laboratory's ranges
Female subjects of childbearing potential (ie, ovulating, premenopausal, or not surgically sterile) and all male subjects must use a medically accepted, highly effective contraceptive regimen during their participation in the study and for 125 days after the last administration of study drug
Male subjects must agree to abstain from sperm donation through 125 days after administration of the last dose of study drug

Exclusion Criteria

Has an eGFR <30 mL/min/1.73 m2 at Screening utilizing the Chronic Kidney Disease Epidemiology Collaboration formula confirmed by the central laboratory
Has an absolute neutrophil count <1.5 x 10/L
Has a white blood cell count <3.0 x 10/L
Has secondary causes of MN (eg, malignancy, hepatitis B or C, human immunodeficiency virus [HIV], systemic lupus erythematosus [SLE], or other autoimmune diseases [eg, thyroiditis], drug-induced)
Has a diagnosis or history of SLE (including non renal disease)
Has type 1 diabetes mellitus
Has an acute, chronic, or latent infection, including tuberculosis, hepatitis, HIV, or chronic urinary tract infections
Is positive for SARS-CoV-2 testing at Screening
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note